Abstract
Objectives As first line therapy, pembrolizumab provides longer progression free survival (PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) with tumor propensity scores (TPS) ≥50%. However, clinical trials do not represent real-world patients. Materials and Methods This multicenter retrospective study conducted across 11 medical centers in Japan analyzed clinical data from patients receiving first-line pembrolizumab for NSCLC between February 1, 2017 and April 30, 2018. The efficacy, safety, and suitability of pembrolizumab monotherapy were evaluated. Results The median age of the 213 enrolled patients was 71 (range: 39-91) years. Among them, 176 (82.6%) were male, 20 (9.4%) were never smokers (median Brinkman index: 900), 172 (80.8%) had an ECOG PS of 0-1, 55 (25.8%) had squamous-cell carcinoma (SQ). PD-L1 TPS were 50-74%, 75-89%, and 90-100% in 97 (45.5%), 47 (22.1%), and 69 (32.4%) patients, respectively. Adverse events (AEs) of grades ≥3 were observed in 39 (18.3%) patients. Pneumonitis was the most common severe AE, occurring in 10 patients (4.7%) including 1 with grade 4 toxicity; no severe AE-related deaths occurred. The overall respons...Continue Reading
References
Feb 25, 1998·Journal of Clinical Epidemiology·A FuksA Riaz
Oct 4, 2000·The Journal of Experimental Medicine·G J FreemanT Honjo
Jul 2, 2002·Nature Medicine·Haidong DongLieping Chen
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Oct 31, 2002·American Journal of Respiratory and Critical Care Medicine·Stephen G Spiro, Joanna C Porter
Mar 18, 2005·Annual Review of Immunology·Rebecca J GreenwaldArlene H Sharpe
Feb 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corey LangerUNKNOWN Eastern Cooperative Oncology Group
May 1, 2009·BMC Cancer·Janette VardyStephen J Clarke
Jul 20, 2010·Immunological Reviews·Loise M FranciscoArlene H Sharpe
Dec 15, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Maria Q BaggstromRamaswamy Govindan
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Sep 6, 2014·Annals of Surgical Oncology·Akiyoshi KinoshitaMasato Matsushima
May 3, 2015·BMC Cancer·Xiao-li WeiRui-hua Xu
Dec 30, 2015·Lancet·Roy S HerbstEdward B Garon
Feb 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara MeloskyVera Hirsh
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Nov 9, 2016·Oncotarget·Fanrong ZhangDan Su
Dec 17, 2016·Lancet·Achim RittmeyerUNKNOWN OAK Study Group
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Nov 15, 2017·Clinical Lung Cancer·Takako InoueFumio Imamura
Apr 17, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Daichi FujimotoToyohiro Hirai
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Jun 24, 2018·Clinical Lung Cancer·Hayato KawachiKeisuke Tomii
Aug 21, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn C ArbourMatthew D Hellmann
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Jan 9, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckJulie R Brahmer
Apr 9, 2019·Lancet·Tony S K MokUNKNOWN KEYNOTE-042 Investigators
Citations
Jan 8, 2020·International Journal of Clinical Oncology·Daichi TamuraWataru Obara
Aug 9, 2020·Lung Cancer : Targets and Therapy·Susumu NoguchiTakakazu Sugita
Jun 1, 2020·Cancer Immunology, Immunotherapy : CII·Alessio CortelliniGiampiero Porzio
Sep 30, 2020·Journal of Immunotherapy·Giulio MetroAlfredo Addeo
Jan 21, 2021·Cancer Management and Research·Xi ChengFang Lou
Mar 3, 2021·Clinical Lung Cancer·Nikolaj FrostChristian Grohé
Mar 2, 2021·Therapeutic Advances in Medical Oncology·Jingjing QuJianying Zhou
Mar 13, 2021·Thoracic Cancer·Taisuke IsonoNoboru Takayanagi
Mar 30, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Francesco FacchinettiMarcello Tiseo
Jun 19, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Bartłomiej TomasikRafał Dziadziuszko
Aug 7, 2021·International Immunopharmacology·Ying WangXuebing Yan
Jul 22, 2021·The Oncologist·Marija IvanovićTanja Cufer
Aug 8, 2021·Cancers·Matteo FranchiGiovanni Corrao
Sep 17, 2021·Wiener klinische Wochenschrift·Sabine Geiger-GritschGeorg Pall